Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nivolumab for symptomatic brain metastases in metastatic melanoma
NL-OMON42782Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in melanoma and brain metastases, sponsored by University Medical Center Groningen. Primary endpoint: Best overall response rate of target brain lesions. Started Aug 2016; status: active, not recruiting.
02
Drugs
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on NL-OMON42782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42782.